FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172116766> ?p ?o ?g. }

• W2172116766 endingPage "1522" @default.
• W2172116766 startingPage "1514" @default.
• W2172116766 abstract "Abstract Aberrant FLT3 expression and/or mutation plays a significant role in leukemogenesis. This has prompted the development of selective small molecule tyrosine kinase inhibitors against FLT3. However, like most tyrosine kinase inhibitors, those against FLT3 are not completely specific and at the doses required to completely inhibit target, significant toxicities may occur. In addition, tyrosine kinase inhibitors for other kinases have been shown to select for cells that become resistant. To overcome some of these limitations we developed two fully human phage display monoclonal antibodies against FLT3 (IMC-EB10 and IMC-NC7). These antibodies inhibited ligand-mediated activation of wild-type FLT3 and constitutively activated mutant FLT3 and in most cell types affected downstream STAT5, AKT, and mitogen-activated protein kinase activation. In addition to interfering with FLT3 signaling, IMC-EB10 and, to a significantly lesser extent, IMC-NC7 initiated antibody-dependent cell-mediated cytotoxicity on FLT3-expressing cells. When IMC-EB10 was used in vivo to treat nonobese diabetic/severe combined immunodeficient mice given injections of primary FLT3/ITD acute myelogenous leukemia samples or myeloid cell lines with FLT3 expression, it significantly decreased engraftment of leukemic cells and increased survival, respectively. In contrast, IMC-EB10 treatment did not reduce engraftment of normal human CD34+ cord blood cells nor did it show any significant inhibition of normal murine hematopoiesis. Thus, these types of antibodies have the potential to be safe and effective new therapeutic agents for acute myelogenous leukemia and possibly other FLT3-expressing malignancies." @default.
• W2172116766 created "2016-06-24" @default.
• W2172116766 creator A5002815845 @default.
• W2172116766 creator A5013214842 @default.
• W2172116766 creator A5018989541 @default.
• W2172116766 creator A5030014755 @default.
• W2172116766 creator A5031028550 @default.
• W2172116766 creator A5041588764 @default.
• W2172116766 creator A5045370280 @default.
• W2172116766 creator A5069066049 @default.
• W2172116766 creator A5071983100 @default.
• W2172116766 creator A5074599944 @default.
• W2172116766 creator A5079048970 @default.
• W2172116766 creator A5088753415 @default.
• W2172116766 creator A5089694123 @default.
• W2172116766 date "2005-02-15" @default.
• W2172116766 modified "2023-09-27" @default.
• W2172116766 title "Inhibitory Anti-FLT3 Antibodies Are Capable of Mediating Antibody-Dependent Cell-Mediated Cytotoxicity and Reducing Engraftment of Acute Myelogenous Leukemia Blasts in Nonobese Diabetic/Severe Combined Immunodeficient Mice" @default.
• W2172116766 cites W134922517 @default.
• W2172116766 cites W1551102474 @default.
• W2172116766 cites W1968306285 @default.
• W2172116766 cites W1969130273 @default.
• W2172116766 cites W1969366020 @default.
• W2172116766 cites W1971028883 @default.
• W2172116766 cites W1978589349 @default.
• W2172116766 cites W1983663468 @default.
• W2172116766 cites W1983999811 @default.
• W2172116766 cites W1985349116 @default.
• W2172116766 cites W1990030298 @default.
• W2172116766 cites W1996606746 @default.
• W2172116766 cites W1999614615 @default.
• W2172116766 cites W2007044832 @default.
• W2172116766 cites W2016054701 @default.
• W2172116766 cites W2034820298 @default.
• W2172116766 cites W2050502992 @default.
• W2172116766 cites W2069057374 @default.
• W2172116766 cites W2071432029 @default.
• W2172116766 cites W2080246905 @default.
• W2172116766 cites W2082219113 @default.
• W2172116766 cites W2082408605 @default.
• W2172116766 cites W2085397716 @default.
• W2172116766 cites W2086567073 @default.
• W2172116766 cites W2092923321 @default.
• W2172116766 cites W2095013649 @default.
• W2172116766 cites W2101886636 @default.
• W2172116766 cites W2106883237 @default.
• W2172116766 cites W2112641034 @default.
• W2172116766 cites W2118781121 @default.
• W2172116766 cites W2120032851 @default.
• W2172116766 cites W2125877707 @default.
• W2172116766 cites W2130864403 @default.
• W2172116766 cites W2132912591 @default.
• W2172116766 cites W2141592427 @default.
• W2172116766 cites W2149032069 @default.
• W2172116766 cites W2253167439 @default.
• W2172116766 cites W2314546113 @default.
• W2172116766 cites W2317475893 @default.
• W2172116766 cites W2331674116 @default.
• W2172116766 cites W256420660 @default.
• W2172116766 cites W32697403 @default.
• W2172116766 cites W4246832952 @default.
• W2172116766 doi "https://doi.org/10.1158/0008-5472.can-04-3081" @default.
• W2172116766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15735040" @default.
• W2172116766 hasPublicationYear "2005" @default.
• W2172116766 type Work @default.
• W2172116766 sameAs 2172116766 @default.
• W2172116766 citedByCount "45" @default.
• W2172116766 countsByYear W21721167662012 @default.
• W2172116766 countsByYear W21721167662013 @default.
• W2172116766 countsByYear W21721167662014 @default.
• W2172116766 countsByYear W21721167662016 @default.
• W2172116766 countsByYear W21721167662018 @default.
• W2172116766 countsByYear W21721167662019 @default.
• W2172116766 countsByYear W21721167662021 @default.
• W2172116766 countsByYear W21721167662022 @default.
• W2172116766 crossrefType "journal-article" @default.
• W2172116766 hasAuthorship W2172116766A5002815845 @default.
• W2172116766 hasAuthorship W2172116766A5013214842 @default.
• W2172116766 hasAuthorship W2172116766A5018989541 @default.
• W2172116766 hasAuthorship W2172116766A5030014755 @default.
• W2172116766 hasAuthorship W2172116766A5031028550 @default.
• W2172116766 hasAuthorship W2172116766A5041588764 @default.
• W2172116766 hasAuthorship W2172116766A5045370280 @default.
• W2172116766 hasAuthorship W2172116766A5069066049 @default.
• W2172116766 hasAuthorship W2172116766A5071983100 @default.
• W2172116766 hasAuthorship W2172116766A5074599944 @default.
• W2172116766 hasAuthorship W2172116766A5079048970 @default.
• W2172116766 hasAuthorship W2172116766A5088753415 @default.
• W2172116766 hasAuthorship W2172116766A5089694123 @default.
• W2172116766 hasConcept C109159458 @default.
• W2172116766 hasConcept C159654299 @default.
• W2172116766 hasConcept C203014093 @default.
• W2172116766 hasConcept C2778461978 @default.
• W2172116766 hasConcept C2778729363 @default.
• W2172116766 hasConcept C28328180 @default.
• W2172116766 hasConcept C41650920 @default.
• W2172116766 hasConcept C42362537 @default.
• W2172116766 hasConcept C502942594 @default.

• next